Identification and assessment of ongoing trials in health technology assessment reviews

Health Technology Assessment

Volumn 8, Issue 44, 2004, Pages

  Song, F J ^a   Fry Smith, A ^b   Davenport, C ^b   Bayliss, S ^b   Adi, Y ^b   Wilson, J S ^b   Hyde, C ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CILENGITIDE; DOCETAXEL; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IODINATED POPPYSEED OIL; MARIMASTAT; MEGLUMINE DIATRIZOATE; MITOXANTRONE; PLACEBO; PLEVITREXED; PROTEIN P30; RECOMBINANT INTERLEUKIN 2; RUBITECAN; TAMOXIFEN; TANOMASTAT; TIPIFARNIB;

ANALYTIC METHOD; BAYES THEOREM; BIBLIOGRAPHIC DATABASE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER RADIOTHERAPY; CANCER SURGERY; CASE STUDY; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DOSE RESPONSE; EMPIRICISM; ENZYME THERAPY; EVIDENCE BASED MEDICINE; HEALTH CARE; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL INFORMATION SYSTEM; MEDICAL LITERATURE; PANCREAS CANCER; PREDICTION; PROBABILITY; PUBLICATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REGISTER; RELIABILITY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 12344332384     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta8440     Document Type: Review

References (110)

1. Hill S, Garattini S, van-Loenhout J, O'Brien BJ, de-Joncheere K. Technology appraisal programme of the National Institute for Clinical Excellence - a review by WHO. Geneva: World Health Organization (Europe), 2003.
2. Khan K, ter-Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking systematic reviews of research on effectiveness - CRD's guidance for those carrying out or commissioning reviews. York: Centre for Reviews and Dissemination, University of York; 2001.
3. Clarke M, Oxman AD. Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. The (Cochrane Library) Issue 2. Oxford: Update Software; 2003.
4. Piantadosi S. Clinical trials - a methodologic perspective New York: John Wiley; 1997.
5. Berry DA. Basic principles in designing and analyzing clinical studies. In Berry DA, editor. Statistical methodology in the pharmaceutical science. New York: Marcel Dekker; 1990. pp. 1-55.
6. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 1995;58:108-17.
7. Borzak S, Ridker PM. Discordance between meta-analyses and large scale randomized, controlled trials; examples from the management of acute myocardial infarction. Ann Intern Med 1995;123 873-7.
8. Fletcher A, Spiegelhalter D, Staessen J, Thijs L, Bulpitt C. Implications for trials in progress of publication of positive results. Lancet 1993; 342:653-7.
9. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. J R Stat Soc A 1994;157 357-416.
10. Song F, Eastwood A, Gilbody S, Duley L, Sutton A. Publication and related biases. Health Technol Assess 2000;4(10).
11. Olsen KL, Hopewell S, Dickersin K, Clarke M, Oxman AD. Publication bias in clinical trials. The Cochrane Library. Issue 3. Oxford: Update Software, 2002.
12. Hopewell S, Clarke M, Stewart L, Tierney J. Time to publication for results of clinical trials. The Cochrane Library. Issue 3. Oxford: Update Software, 2002.
13. Cappelleri JC, Ioannidis JP, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, et al. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA 1996;276 1332-8.
14. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.
15. Villar J, Carroli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet 1995; 345 772-6.
16. Scott R. Answering the unanswered questions: ongoing trials of statins and antihypertensives in type 2 diabetes. Acta Diabetol 2002; 39 Suppl 2:S46-51.
17. Chalmers I. Using systematic reviews and registers of ongoing trials for scientific and ethical trial design, monitoring, and reporting. In Egger M, Davey-Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. London: BMJ Books; 2000. pp. 429-43.
18. Laupacis A, Connolly SJ, Gent M, Roberts RS, Cairns J, Joyner C. How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med 1991;115 818-22.
19. Dickersin K. Report from the panel on the Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials. Control Clin Trials 1988;9:76-81.
20. Manheimer E, Anderson D. Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility. BMJ 2002;325:528-31.
21. Carpenter LM. Is the study worth doing? Lancet 1993; 342:221-3.
22. Parmar MKB, Ungerleider RS, Simon R. Assessing whether to perform a confirmatory randomized clinical trial. J Nat Cancer Inst 1996;88:1645-51.
23. Sutton AJ, Song F, Gilbody SM, Abrams KR. Modelling publication bias in meta-analysis: a review. Stat Methods Med Res 2000;9:421-45.
24. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995; 48:45-57.
25. Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR. Methods for exploring heterogeneity in meta-analysis. Eval Health Profess 2001;24:126-51.
26. Abrams K, Ashby D, Errington D. Simple Bayesian analysis in clinical trials: a tutorial. Control Clin Trials 1994;15 349-59.
27. Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis: an application to a policy model of Alzheimer disease. Int J Technol Assess Health Care 2001;17 38-55.
28. Edwards S, Lilford RJ, Kiauka S. Different types of systematic review in health services research. In Black N, Brazier J, Fitzpatrick R, Reeves B, editors. Health services research methods: a guide to best practice. London: BMJ Books; 1998. pp. 255-9.
29. Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technol Assess 2002;6(18).
30. Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess 2002;6(9).
31. Chilcott J, Wight J, Lloyd JM, Tappenden P. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review. Health Technol Assess 2001; 5(19).
32. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess 2001;5(32).
33. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. The clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001;5(1).
34. Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000;4(9).
35. Clegg AJ, Colquitt J, Sidhu MK, Royle P, Loveman E, Walker A. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 2002;6(12).
36. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess 2002;6(17).
37. Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, et al. The management of dyspepsia: a systematic review. Health Technol Assess 2000;4(39).
38. Dinnes J, Cave C, Huang S, Major K, Milne R. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. Health Technol Assess 2001;5(13).
39. Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health Technol Assess 2001;5(28).
40. Hyde C, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C, et al. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment. Health Technol Assess 2002;6(2).
41. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6(21).
42. Jobanputra P, Parry D, Fry-Smith A, Burls A. Effectiveness of autologous chondrocyte transplantation for hyaline cartilage defects in knees: a rapid and systematic review. Health Technol Assess 2001; 5(11).
43. Lewis R, Bagnall AM, King S, Woolacott N, Forbes C, Shirran L, et al. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. Health. Technol Assess 2002;6(14).
44. Lewis R, Bagnall AM, Forbes C, Shirran E, Duffy S, Kleijnen J, et al. The clinical effectiveness of trastuzumab for breast cancer: a systematic review. Health Technol Assess 2002;6 13).
45. Lewis R, Whiting P, ter Riet G, O'Meara S, Glanville J. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention. Health Technol Assess 2001; 5 14).
46. Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess 2000;4(17).
47. Lloyd JM, Hummel S, Bansback N, Orr B, Seymour M. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001;5(25).
48. McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. Health Technol Assess 2000;4 30).
49. Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol Assess 2000;4 23).
50. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess 2002;6(6).
51. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001;5(18).
52. Parkes J, Bryant J, Milne R. Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review. Health Technol Assess 2000;4(26).
53. Payne N, Chilcott J, McGoogan E. Liquid-based cytology in cervical screening: a rapid and systematic review. Health Technol Assess 2000;4(18).
54. Peters J, Stevenson M, Beverley C, Lim JN, Smith S. The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation. Health Technol Assess 2002; 6 5).
55. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4 33).
56. Song F, O'Meara S, Wilson P, Golder S, Kleijnen J. The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth. Health Technol Assess 2000;4(15).
57. Stewart A, Sandercock J, Bryan S, Hyde C, Barton PM, Fry-Smith A, et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technol Assess 2001;5(2).
58. Vale L, Wyness L, McCormack K, McKenzie L, Brazzelli M, Stearns SC. A systematic review of the effectiveness and cost-effectiveness of metal-on-metal hip resurfacing arthroplasty for treatment of hip disease. Health Technol Assess 2002;6(15).
59. Wake B, Hyde C, Bryan S, Barton P, Song F, Fry-Smith A, et al. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technol Assess 2002;6(3).
60. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002;6(16).
61. McNamee D. Review of clinical protocols and The Lancet. Lancet 2003;357:1819.
62. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290:516-23.
63. Tonks A. Registering clinical trials. BMJ 1999; 319 1565-8.
64. Current controlled trials' strategy for supporting the continued development of the mRCT and ISRTN scheme CCT strategic review. 2001.
65. Marley C, Godlee F, Chalmers I. An International MetaRegister and unique identification system for randomised trials. Control Clin Trials 2001;22:33S.
66. Fayers P. UKCCR Register of UK Cancer Trials. Control Clin Trials 1995;16:172-81.
67. Chollar SA. A registry for clinical trials. Ann Intern Med 1998;128:701-2.
68. Lee H. The EU-PSI project: the story so far. Cochrane Dementia and Cognitive Improvement Group Newsletter 2001;(5):4-5.
69. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003;290:495-501.
70. Scherer R, Langenberg P. Full publication of results initially presented in abstract: revisited (Cochrane Methodology Review). The Cochrane Library. Issue 1. Chichester: John Wiley; 2004.
71. Glanville J. Finding trials on the Internet: selected resources. York: University of York, NHS Centre for Reviews and Dissemination; 2002.
72. Royle P, Bidwell S. Searching for randomised controlled trials in meeting abstracts. Health Technol Assess (ISTACH Newsletter 2000;5.
73. Vickers AJ, Smith C. Incorporating data from dissertations in systematic reviews. Int J Technol Assess Health Care 2000; 16 711-13.
74. MacLean H, Morton SC, Ofman J, Roth ER, Shekelle PG. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol 2003;56:44-51.
75. Bennett DA, Jull A. FDA: untapped source of unpublished trials. Lancet 2003;361:1402-3.
76. Moore A, McQuay H. Mindstretcher - does unpublished information make a difference? Bandolier 2003;110:5.
77. Roberts I, Po AL, Chalmers I. Intellectual property, drug licensing, freedom of information, and public health. Lancet 1998;352:726-9.
78. Gibbs TE, Wager E. Realities of trial registration: the Glaxo Wellcome experience. Int J Pharm Med 2000;14:203-5.
79. Sykes R. Being a modern pharmaceutical company: involves making information available on clinical trial programmes. BMJ 1998;317:1172.
80. Pharmaceutical industry leads world in launching scheme to register clinical trials in UK. Cochrane News 2000;(4).
81. Eysenbach G, Wyatt J. Using the internet for surveys and health research. J Med Internet Res 2002;4:E13.
82. Adelhard K, Obst O. Evaluation of medical internet sites. Methods Inf Med 1999;38:75-9.
83. Wyatt JC. Commentary: measuring quality and impact of the world wide web. BMJ 1997; 314:1879-81.
84. Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess 2003;7(1).
85. Savoie I, Helmer D, Green CJ, Kazanjian A. Beyond Medline: reducing bias through extended systematic review search. Int J Technol Assess Health Care 2003;19:168-78.
86. Suarez-Almazor ME, Belseck E, Homik J, Dorgan M, Ramos RC. Identifying clinical trials in the medical literature with electronic databases: MEDLINE alone is not enough. Control Clin Trials 2000; 21:476-87.
87. Royle P, Milne R. Literature searching for randomised controlled trials used in Cochrane reviews: rapid versus exhaustive searches. Int J Technol Assess Health Care 2003;19:591-603.
88. Chan AW, and Altman DG. Discrepancies between protocols and publications: evidence of outcome reporting bias in randomised trials. Presented at the XI Cochrane Colloquium - Evidence, Health Care and Culture. Barcelona; 26-31 October, 2003.
89. Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 1998;317:1185-90.
90. Song F, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000; 21:488-97.
91. Gotzsche PC, Liberati A, Torri V, Rossetti L. Beware of surrogate outcome measures. Int J Technol Assess Health Care 1996;12:238-46.
92. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
93. Juni P, Altman D, Egger M. Systematic reviews in health care - assessing the quality of controlled clinical trials. BMJ 2001; 323:42-6.
94. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54.
95. Ioannidis JPA, Contopoulos DG, Lau J. Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. J Clin Epidemiol 1999;52:281-91.
96. Henderson WG, Moritz T, Goldman S, Copeland J, Sethi G. Use of cumulative meta-analysis in the design, monitoring, and final analysis of a clinical trial: a case study. Control Clin Trials 1995; 16 331-41.
97. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci USA 2001;98:831-6.
98. Mullen B, Muellerleile P, Bryant B. Cumulative meta-analysis: a consideration of indicators of sufficiency and stability. Pers Soc Psychol Bull 2001;27:1450-62.
99. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 1997;18:580-93.
100. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 3:659-63.
101. Halperin M, Lan KK, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in long-term clinical trials. Control Clin trials 1982; 3:311-23.
102. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics 1988;44:579-85.
103. Rosenthal R. The "file drawer problem" and tolerance for null results. Psychol Bull 1979; 86:638-41.
104. Carson KP, Schriesheim CA, Kinicki AJ. The usefulness of the "fail-safe" statistic in meta-analysis. Educ Psychol Meas 1990; 50:233-43.
105. Spiegelhalter DJ, Myles PJ, Jones DR, Abrams KR. An introduction to bayesian methods in health technology assessment. BMJ 1999;319:508-12.
106. Fayers PM, Ashby D, Parmar MKB. Tutorial in biostatistics. Bayesian data monitoring in clinical trials. Stat Med 1997; 16 1413-30.
107. Ward S, Morris E, Bansback N, Calvert N, Crellin A, Forman D, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. Health Technol Assess 1997;5(24).
108. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15 2403-13.
109. Spielgelhalter D, Abrames KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. WileyEurope; 2003.
110. Wilson J, Connock M, Song FJ, Yao G, Fry-Smith A, Raftery J, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: a systematic review and economic evaluation. Health Technol Assess in press.